Orphan Drugs

Small-batch GMP manufacturing and packaging for rare disease products, built on QbD and control strategy.

orphan drugs banner
Niche-market therapies

Flexible supply
for Orphan Drugs 

Groupe PARIMA supports orphan drug programs with integrated development, GMP manufacturing, and packaging for non-sterile dosage forms. We define a clear control strategy, align analytical methods, and execute repeatable batches to maintain consistent product performance on scale-up.

Small-volume GMP execution

We translate development knowledge into a production-ready process, bringing the same team across phases to ensure process controls, documentation readiness, and packaging execution for reliable supply.

Designed for consistency

We establish critical process parameters and product CQAs to support validation and lifecycle consistency.

Right-size manufacturing

We run small and mid-scale batches with defined parameters that stay reproducible as demand evolves.

Packaging and compatibility

We support extractables and leachables and run compatibility studies to align formulation and packaging.

Adapted to your program

Our methodology tailors process design, control strategy, and capacity to your orphan program’s reality.

define product requirements

Define Product Requirements

Align the target product profile and packaging format that drives execution.

build the process and controls

Build the process and controls

Design a dedicated process and define the control strategy for consistent performance.

lock analytical readiness

Lock analytical readiness

Set specifications and validate fit‑for‑purpose methods to support release and stability.

Execute GMP Manufacturing

Execute GMP manufacturing

Run GMP batches with in‑process controls, documentation readiness, and integrated packaging execution.

Sustain routine Supply

Sustain routine supply

Prepare validation readiness and manage lifecycle changes to keep supply consistent over time.

Our Capabilities

Designed for small‑volume programs, with end‑to‑end control from development through GMP production.

Adapted to evolving programs
Adapted to evolving programs

Orphan drug products evolve quickly. We translate it into a production-ready process, with a defined control strategy and documentation to support scale‑up and supply.

  • We formalize process knowledge and batch records to support smooth progression into GMP manufacture.
  • We define critical process parameters and in‑process controls to keep performance consistent across phases.
Release control from clinical to supply
Release control from clinical to supply

Orphan drug products require consistent, defensible release. We define methods, strategy, and stability execution to maintain control from clinical to routine supply.

  • We align analytical strategy with product risks, phase needs, and GMP release requirements.
  • We generate stability data and maintain controlled updates to keep supply consistent over time.

Our Services

Designed for rare disease programs, combining development, analytical readiness, and GMP small‑batch manufacturing.

01
Product development icon
Product Development

Manufacturing-ready development that reduces rework later, with decisions that scale as requirements increase.

02
Analytical services icon
Analytical Services

Clear data for decision-making stability plans, and confident release as your program progresses.

03
icn_Manufacturing_white
Manufacturing & Packaging

Consistent execution designed for predictable release and routine supply, with controlled changes over time.

We offer QbD-led execution with defined controls for consistent small‑volume manufacturing and packaging.

Ressources

Explore practical insights on developing, manufacturing, and packaging rare disease drug products.

White papers
2026/07/06
How Drug Product Formulation Works: Topical, Oral, and Nasal Liquid and Semi-Solid Dosage Forms
White papers
2026/07/03
How Early API Characterization Can Reduce Formulation and Scale-up Risks
White papers
2026/07/06
How Drug Product Formulation Works: Topical, Oral, and Nasal Liquid and Semi-Solid Dosage Forms
White papers
2026/07/03
How Early API Characterization Can Reduce Formulation and Scale-up Risks

Contact Us

Have a rare disease project in progress?

Talk with our team about development, analytical readiness, and small-batch GMP manufacturing and packaging for non-sterile drug products.